<DOC>
	<DOC>NCT00170625</DOC>
	<brief_summary>Compatibility of the topotecan therapy in combination with carboplatin.</brief_summary>
	<brief_title>Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Age &gt;= 18 years patient with ovarian cancer after primary therapy bone marrow function leukocytes &gt;= 4,0 x 109/ l, platelets &gt;= 100 109/l, hemoglobin &gt;= 9 g/dl renal function creatinin &lt;= 1,5 mg% or creatinin clearance &gt;= 60 ml/min liver function bilirubin &lt;= 2,0 mg/dl, SGOT, SGPT and AP within 3 fold of the reference laboratory's normal range ECOG &lt;= 2 Intention of regular followup visits for the duration of the study written informed consent any known hypersensitivity against topotecan isomeraseIinhibitor other medication included in the study protocol ECOG &gt; 2 patients with radiotherapy within the last 4 weeks</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>platin-resistant</keyword>
</DOC>